SpectraCure AB (SPEC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SpectraCure AB (SPEC) has a cash flow conversion efficiency ratio of -0.048x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.48 Million ≈ $-482.55K USD) by net assets (Skr93.55 Million ≈ $10.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SPEC net asset quality index to measure how much of total assets are equity-financed.
SpectraCure AB - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how SpectraCure AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SpectraCure AB (SPEC) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
SpectraCure AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SpectraCure AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polledo S.A.
BA:POLL
|
0.130x |
|
Stayble Therapeutics AB
ST:STABL
|
-0.194x |
|
Forward Water Technologies Corp
V:FWTC
|
-0.052x |
|
Springfield Properties Plc
LSE:SPR
|
-0.100x |
|
Erech Finance Cahalacha Ltd
TA:EFNC
|
-0.213x |
|
Rainbow Polikarbonat Sanayi Ticaret AS
IS:RNPOL
|
0.103x |
|
Nexoptic Technology Corp
V:NXO
|
-0.011x |
|
Moovly Media Inc
V:MVY
|
0.016x |
Annual Cash Flow Conversion Efficiency for SpectraCure AB (2014–2025)
The table below shows the annual cash flow conversion efficiency of SpectraCure AB from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see SPEC market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr93.55 Million ≈ $10.07 Million |
Skr-24.03 Million ≈ $-2.59 Million |
-0.257x | -25.74% |
| 2024-12-31 | Skr106.86 Million ≈ $11.50 Million |
Skr-21.83 Million ≈ $-2.35 Million |
-0.204x | -41.99% |
| 2023-12-31 | Skr129.86 Million ≈ $13.97 Million |
Skr-18.68 Million ≈ $-2.01 Million |
-0.144x | +5.84% |
| 2022-12-31 | Skr150.30 Million ≈ $16.17 Million |
Skr-22.96 Million ≈ $-2.47 Million |
-0.153x | -44.27% |
| 2021-12-31 | Skr175.68 Million ≈ $18.91 Million |
Skr-18.60 Million ≈ $-2.00 Million |
-0.106x | -122.07% |
| 2020-12-31 | Skr197.22 Million ≈ $21.22 Million |
Skr-9.40 Million ≈ $-1.01 Million |
-0.048x | +58.37% |
| 2019-12-31 | Skr87.78 Million ≈ $9.45 Million |
Skr-10.05 Million ≈ $-1.08 Million |
-0.115x | +17.12% |
| 2018-12-31 | Skr64.92 Million ≈ $6.99 Million |
Skr-8.97 Million ≈ $-965.53K |
-0.138x | -129.30% |
| 2017-12-31 | Skr13.41 Million ≈ $1.44 Million |
Skr6.33 Million ≈ $680.77K |
0.472x | +153.22% |
| 2016-12-31 | Skr22.11 Million ≈ $2.38 Million |
Skr-19.60 Million ≈ $-2.11 Million |
-0.886x | -19.15% |
| 2015-12-31 | Skr13.06 Million ≈ $1.41 Million |
Skr-9.71 Million ≈ $-1.05 Million |
-0.744x | -482.81% |
| 2014-12-31 | Skr-3.11 Million ≈ $-334.73K |
Skr-604.49K ≈ $-65.05K |
0.194x | -- |
About SpectraCure AB
SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.